Importance Currently there is no drug therapy for abdominal aortic aneurysm (AAA).
Objective To test the efficacy of the angiotensin receptor blocker telmisartan in slowing AAA …

Background Experimental studies suggest that angiotensin II plays a central role in the
pathogenesis of abdominal aortic aneurysm. This trial aims to evaluate the efficacy of the …

Aims The AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition
on RisK) trial investigated whether ACE-inhibition reduces small abdominal aortic …

Abdominal aortic aneurysm (AAA) causes∼ 170 000 deaths annually worldwide. Most
guidelines recommend asymptomatic small AAAs (30 to< 50 mm in women; 30 to< 55 mm in …

Background Pharmacotherapy may represent a potential means to limit the expansion rate
of abdominal aortic aneurysms (AAAs). Studies evaluating the efficacy of different …

Background Management of abdominal aortic aneurysms (AAAs) relies on surgical repair of
larger AAAs. Consequently medical interventions inhibiting AAA progression could greatly …

Background: To evaluate the effect of statins on the annual expansion rate (ER) of small
infrarenal abdominal aortic aneurysms (AAA). Patients and methods: All patients under …

Background No effective treatment is currently available to prevent progression of small and
medium-sized abdominal aortic aneurysms (AAAs). Identification of drugs with sufficient …

Objective This review describes ongoing efforts to develop a medical therapy to limit
abdominal aortic aneurysm (AAA) growth. Methods Data from animal model studies, human …

Abdominal aortic aneurysm (AAA) is a severe vascular disease and a major public health
issue with an unmet medical need for therapy. This disease is featured by a progressive …